Toll Free: 1-888-928-9744

ContraFect Corporation - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 35 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

ContraFect Corporation - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'ContraFect Corporation - Product Pipeline Review - 2014', provides an overview of the ContraFect Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ContraFect Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of ContraFect Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of ContraFect Corporation's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the ContraFect Corporation's pipeline products

Reasons to buy

- Evaluate ContraFect Corporation's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of ContraFect Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the ContraFect Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of ContraFect Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of ContraFect Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of ContraFect Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
ContraFect Corporation Snapshot 5
ContraFect Corporation Overview 5
Key Information 5
Key Facts 5
ContraFect Corporation - Research and Development Overview 6
Key Therapeutic Areas 6
ContraFect Corporation - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
ContraFect Corporation - Pipeline Products Glance 11
ContraFect Corporation - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
ContraFect Corporation - Drug Profiles 13
CF-301 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
CF-401 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
CF-402 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
CF-403 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
CF-404 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Monoclonal Antibody 1 for Influenza 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CF-302 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CF-303 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CF-304 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
CF-305 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CF-306 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
CF-307 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
CF-308 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
CF-309 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Monoclonal Antibodies for Influenza 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ContraFect Corporation - Pipeline Analysis 28
ContraFect Corporation - Pipeline Products by Target 28
ContraFect Corporation - Pipeline Products by Molecule Type 29
ContraFect Corporation - Pipeline Products by Mechanism of Action 30
ContraFect Corporation - Recent Pipeline Updates 31
ContraFect Corporation - Dormant Projects 32
ContraFect Corporation - Locations And Subsidiaries 33
Head Office 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35
List of Tables
ContraFect Corporation, Key Information 5
ContraFect Corporation, Key Facts 5
ContraFect Corporation - Pipeline by Indication, 2014 8
ContraFect Corporation - Pipeline by Stage of Development, 2014 9
ContraFect Corporation - Monotherapy Products in Pipeline, 2014 10
ContraFect Corporation - Preclinical, 2014 11
ContraFect Corporation - Discovery, 2014 12
ContraFect Corporation - Pipeline by Target, 2014 28
ContraFect Corporation - Pipeline by Molecule Type, 2014 29
ContraFect Corporation - Pipeline Products by Mechanism of Action, 2014 30
ContraFect Corporation - Recent Pipeline Updates, 2014 31
ContraFect Corporation - Dormant Developmental Projects,2014 32 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify